LON:RENE - ReNeuron Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 53.50 0.00 (0.00 %)
(As of 12/9/2018 04:00 PM ET)
Previous CloseGBX 53.50
Today's RangeGBX 52 - GBX 53.89
52-Week RangeGBX 1.37 - GBX 142.50
Volume10,831 shs
Average Volume28,700 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Receive RENE News and Ratings via Email

Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:RENE
Previous Symbol
CUSIPN/A
Phone+44-20-38198400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees62
Outstanding SharesN/A
Market Cap£0.00
OptionableNot Optionable

ReNeuron Group (LON:RENE) Frequently Asked Questions

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How were ReNeuron Group's earnings last quarter?

ReNeuron Group Plc (LON:RENE) announced its earnings results on Thursday, July, 12th. The company reported ($55.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($61.20) by $5.50. View ReNeuron Group's Earnings History.

Has ReNeuron Group been receiving favorable news coverage?

News coverage about RENE stock has trended somewhat positive this week, InfoTrie reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ReNeuron Group earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.

Who are some of ReNeuron Group's key competitors?

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the folowing people:
  • Mr. Olav Hellebø, CEO & Director (Age 53)
  • Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 55)
  • Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 67)
  • Dr. Randolph Corteling, Head of Research
  • Ms. Sharon Grimster, VP of Devel. & GM of Wales (Age 59)

How do I buy shares of ReNeuron Group?

Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ReNeuron Group's stock price today?

One share of RENE stock can currently be purchased for approximately GBX 53.50.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is http://www.reneuron.com/.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.


MarketBeat Community Rating for ReNeuron Group (LON RENE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote "Outperform" if you believe RENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2018 by MarketBeat.com Staff

Featured Article: Bull Market

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel